• Skip to content
  • Skip to primary sidebar
Veloxis
  • Home
  • Company
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents
  • Products
    • Our Technology
    • ENVARSUS XR
  • News & Releases
  • Careers
  • Contact Us
Home / Company / Board of Directors

Board of Directors

Masaya Etoh — Chairman

Chairman of the board of directors of Asahi Kasei Pharma Denmark A/S, CVR-no.: 40948074.

Mr. Etoh has over 20 years of experience in the pharmaceutical industry, from business development and strategy to drug discovery and development. He also established a CVC investment function in Asahi Kasei Pharma Corporation. Mr. Etoh holds a Ph.D. from Tokyo Medical and Dental University and MSc from Kyushu Institute of Technology.

Masaya Etoh will be an independent board member.

Daisuke Matsuo — Board Member

Manager and director of Asahi Kasei Pharma Denmark A/S, CVR-no.: 40948074.

Mr. Matsuo joined Asahi Kasei Pharma Corporation in July 2012 as Manager of Corporate Planning and now General Manager of Corporate Planning. Prior to joining Asahi Kasei Pharma, Mr. Matsuo had been Senior Consultant at Nomura Research Institute for 10 years. In addition, Mr. Matsuo has held commercial banking roles at MUFJ Bank, Ltd for 7 years. Mr. Matsuo holds a Bachelor of Faculty of Commerce from Keio University.

Daisuke Matsuo will be an independent board member.

Matthew Ryan Dumont — Board Member

Dumont Director of Asahi Kasei Pharma Denmark A/S, CVR-no.: 40948074.

Mr. Dumont joined Asahi Kasei Pharma America in April 2019 as Director of Corporate Development. Mr. Dumont has 10 years of commercial experience in business and corporate development within the biopharmaceutical and medical device industries. Prior to joining Asahi Kasei, Mr. Dumont was Director of Strategy and Corporate Development at PerkinElmer, Inc. In addition, Mr. Dumont has held corporate development roles at Mylan Pharmaceuticals and Catalent Pharma Solutions. Mr. Dumont holds a Bachelor and Masters of Science in Chemical Engineering from the Johns Hopkins University and a Master of Business Administration from Columbia University.

Matthew Ryan Dumont will be an independent board member.

Primary Sidebar

Company

  • Overview
  • Management Team
  • Board of Directors

News & Releases

  • Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program
    Jun 18, 2020
  • Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020
    Feb 17, 2020
  • Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S’ Request for Delisting of its Shares from Nasdaq Copenhagen A/S
    Jan 29, 2020

Read More

©2018 All rights reserved. Veloxis Pharmaceuticals, Inc. ENV-18-061.1 06/18

info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET

©2018 All rights reserved. Veloxis Pharmaceuticals, Inc. ENV-18-065.1 06/18

info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET

Sitemap | Contact | Privacy Policy | Disclaimer

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.